Get the Stockscreener App
2.59
1.77%
0.045
After Hours:
2.60
0.01
+0.39%
Alector Inc stock is traded at $2.59, with a volume of 2.73M.
It is up +1.77% in the last 24 hours and down -48.92% over the past month.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
See More
Previous Close:
$2.545
Open:
$2.55
24h Volume:
2.73M
Relative Volume:
3.51
Market Cap:
$253.65M
Revenue:
$97.06M
Net Income/Loss:
$-130.39M
P/E Ratio:
-1.5058
EPS:
-1.72
Net Cash Flow:
$-186.54M
1W Performance:
-34.26%
1M Performance:
-48.92%
6M Performance:
-48.20%
1Y Performance:
-52.30%
1-Day Range:
$2.41
$2.685
1-Week Range:
$2.37
$4.18
52-Week Range:
$2.37
$8.90
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
2.59 | 253.65M | 97.06M | -130.39M | -186.54M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Braidwell LP Cuts Stock Position in Alector, Inc. (NASDAQ:ALEC) - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Alector (NASDAQ:ALEC) Stock Price - MarketBeat
Q1 Earnings Estimate for Alector Issued By HC Wainwright - MarketBeat
Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates - Simply Wall St
Victory Capital Management Inc. Increases Position in Alector, Inc. (NASDAQ:ALEC) - Defense World
Alector (NASDAQ:ALEC) Stock Rating Lowered by Morgan Stanley - Defense World
Alector shares price target cut, retains buy amid clinical trial setback - Investing.com Australia
Alector: Bleak Prospects After Alzheimer's Failure (NASDAQ:ALEC) - Seeking Alpha
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Alector price target lowered to $7 from $35 at H.C. Wainwright - Yahoo Finance
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal - The Pharma Letter
Alector (NASDAQ:ALEC) Given New $5.00 Price Target at BTIG Research - Defense World
Alector stock hits 52-week low at $2.61 amid market challenges - Investing.com Canada
Morgan Stanley Downgrades Alector (ALEC) - MSN
Layoff tracker: BMS, Alector and Medigene part ways with staff - PharmaLive
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial By Investing.com - Investing.com Canada
Alector drops 31% as Alzheimer's candidate fails in phase 2 trial - MSN
Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views - Benzinga
Stock market news: Alector down -34.47%, SiNtx Technologies -32.97% among the biggest losers during mid day trading - Business Upturn
Alector Follows Cassava With An Alzheimer’s Miss - Citeline
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce - Inkl
Stock market today: Alector -33.59%, Kohl's Corporation -21.07% among biggest losers in early trading - Business Upturn
Morgan Stanley cuts Alector to underweight, slashes target on clinical study - Investing.com
Alector (NASDAQ:ALEC) Rating Lowered to "Underweight" at Morgan Stanley - MarketBeat
Alector stock drops after Alzheimer’s drug fails in Phase II trial - Yahoo! Voices
Alector turns to layoffs as Alzheimer’s drug fails - BioPharma Dive
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial - Investing.com
Leslie's Posts Weak Results, Joins Zoom Video And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff - BioSpace
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket - Benzinga
Alector's AbbVie-partnered Alzheimer's bid fails mid-stage study - FirstWord Pharma
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2 - Fierce Biotech
Alector halts Alzheimer's trial after missing primary endpoint By Investing.com - Investing.com Canada
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial - STAT
Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint - MarketWatch
Alector halts Alzheimer's trial after missing primary endpoint - Investing.com
Alector Restructures After Alzheimer’s Trial Misses Goal - TipRanks
Alector halts Alzheimer's trial as drug fails key goal By Investing.com - Investing.com South Africa
Alector halts Alzheimer's trial as drug fails key goal - Investing.com
Alector announces AL002 trial misses endpoint, reduces workforce by 17% - TipRanks
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial - GlobeNewswire
Alector's Alzheimer's Drug Fails Phase 2 Trial, Forces 17% Staff Cut | ALEC Stock News - StockTitan
Alector’s Strategic Advances in Immuno-Neurology - TipRanks
Stifel Upgrades Alector (ALEC) - MSN
Goldman Sachs maintains sell on Alector, target $4 amid Alzheimer's study - Investing.com India
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Alector stock hits 52-week low at $4.05 amid market challenges - Investing.com Canada
Alector, Inc. (NASDAQ:ALEC) Shares Sold by US Bancorp DE - Defense World
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates - MSN
Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors - Marketscreener.com
Alector secures $50 million credit facility from Hercules Capital - Investing.com India
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):